StreetAccount Summary: Notable Drug Events expected for the week of 1-Nov
Follow-up: Exelixis now expects readout for STELLAR-304 in Q1 of 2027 ($66.20, 0.00)
GSK Plc downgraded to hold from buy at Jefferies (pre-European open) (1803.0000p, -29)
Powered by FactSet Research Systems Inc.